Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin

Overview

Journal Clin Pharmacol Ther

Publisher Wiley

Specialty Pharmacology

Date 2008 Feb 29

PMID 18305455

Citations 304

Authors

B F Gage

C Eby

J A Johnson

E Deych

M J Rieder

P M Ridker

P E Milligan

G Grice

P Lenzini

A E Rettie

C L Aquilante

L Grosso

S Marsh

T Langaee

L E Farnett

D Voora

D L Veenstra

R J Glynn

A Barrett

H L McLeod

Affiliations

Soon will be listed here.

Abstract

Initiation of warfarin therapy using trial-and-error dosing is problematic. Our goal was to develop and validate a pharmacogenetic algorithm. In the derivation cohort of 1,015 participants, the independent predictors of therapeutic dose were: VKORC1 polymorphism -1639/3673 G>A (-28% per allele), body surface area (BSA) (+11% per 0.25 m(2)), CYP2C9(*)3 (-33% per allele), CYP2C9(*)2 (-19% per allele), age (-7% per decade), target international normalized ratio (INR) (+11% per 0.5 unit increase), amiodarone use (-22%), smoker status (+10%), race (-9%), and current thrombosis (+7%). This pharmacogenetic equation explained 53-54% of the variability in the warfarin dose in the derivation and validation (N= 292) cohorts. For comparison, a clinical equation explained only 17-22% of the dose variability (P < 0.001). In the validation cohort, we prospectively used the pharmacogenetic-dosing algorithm in patients initiating warfarin therapy, two of whom had a major hemorrhage. To facilitate use of these pharmacogenetic and clinical algorithms, we developed a nonprofit website, http://www.WarfarinDosing.org.

Citing Articles

Comparative performance of pharmacogenetics-based warfarin dosing algorithms in Chinese population: use of a pharmacokinetic/pharmacodynamic model to explore dosing regimen through clinical trial simulation.

Shi K, Deng J Pharmacogenet Genomics. 2024; 34(9):275-284.

PMID: 39356590 PMC: 11424055. DOI: 10.1097/FPC.0000000000000545.

Clinical versus fixed warfarin dosing and the impact on quality of anticoagulation (The ClinFix trial).

Fahmi A, Bardissy A, Saad M, Elshafei M, Bader L, Mahfouz A Clin Transl Sci. 2024; 17(6):e13797.

PMID: 38859626 PMC: 11164972. DOI: 10.1111/cts.13797.

QPGx-CARES: Qatar pharmacogenetics clinical applications and research enhancement strategies.

Abdel-Latif R, Badji R, Mohammed S, Al-Muftah W, Mbarek H, Darwish D Clin Transl Sci. 2024; 17(6):e13800.

PMID: 38818903 PMC: 11140449. DOI: 10.1111/cts.13800.

Potential Drug-Nutrient Interactions of 45 Vitamins, Minerals, Trace Elements, and Associated Dietary Compounds with Acetylsalicylic Acid and Warfarin-A Review of the Literature.

Renaud D, Holler A, Michel M Nutrients. 2024; 16(7).

PMID: 38612984 PMC: 11013948. DOI: 10.3390/nu16070950.

Cardiovascular precision medicine - A pharmacogenomic perspective.

Padmanabhan S, Du Toit C, Dominiczak A Camb Prism Precis Med. 2024; 1:e28.

PMID: 38550953 PMC: 10953758. DOI: 10.1017/pcm.2023.17.

References

Millican E, Lenzini P, E Milligan P, Grosso L, Eby C, Deych E . Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood. 2007; 110(5):1511-5. PMC: 1975838. DOI: 10.1182/blood-2007-01-069609. View

Aithal G, Day C, Kesteven P, Daly A . Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999; 353(9154):717-9. DOI: 10.1016/S0140-6736(98)04474-2. View

Voora D, Eby C, Linder M, E Milligan P, Bukaveckas B, McLeod H . Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb Haemost. 2005; 93(4):700-5. DOI: 10.1160/TH04-08-0542. View

Higashi M, Veenstra D, Kondo L, Wittkowsky A, Srinouanprachanh S, Farin F . Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002; 287(13):1690-8. DOI: 10.1001/jama.287.13.1690. View

Lenzini P, Grice G, E Milligan P, Gatchel S, Deych E, Eby C . Optimal initial dose adjustment of warfarin in orthopedic patients. Ann Pharmacother. 2007; 41(11):1798-804. DOI: 10.1345/aph.1K197. View

King C, Porche-Sorbet R, Gage B, Ridker P, Renaud Y, Phillips M . Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose. Am J Clin Pathol. 2008; 129(6):876-83. DOI: 10.1309/1E34UAPR06PJ6HML. View

Ageno W, Squizzato A, Dentali F, Crowther M . Tailoring warfarin induction doses to reflect individual and disease-specific factors. Am J Med. 2005; 118(2):143-4. DOI: 10.1016/j.amjmed.2004.11.015. View

Shine D, Patel J, Kumar J, Malik A, Jaeger J, Maida M . A randomized trial of initial warfarin dosing based on simple clinical criteria. Thromb Haemost. 2003; 89(2):297-304. View

DAmbrosio R, DAndrea G, Cappucci F, Chetta M, Di Perna P, Brancaccio V . Polymorphisms in factor II and factor VII genes modulate oral anticoagulation with warfarin. Haematologica. 2004; 89(12):1510-6. View

10.

Gage B, Eby C, E Milligan P, Banet G, Duncan J, McLeod H . Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost. 2003; 91(1):87-94. DOI: 10.1160/TH03-06-0379. View

11.

Linder M, Looney S, Adams 3rd J, Johnson N, Antonino-Green D, Lacefield N . Warfarin dose adjustments based on CYP2C9 genetic polymorphisms. J Thromb Thrombolysis. 2003; 14(3):227-32. DOI: 10.1023/a:1025052827305. View

12.

Wu A . Use of genetic and nongenetic factors in warfarin dosing algorithms. Pharmacogenomics. 2008; 8(7):851-61. DOI: 10.2217/14622416.8.7.851. View

13.

Beyth R, Quinn L, Landefeld C . A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized, controlled trial. Ann Intern Med. 2000; 133(9):687-95. DOI: 10.7326/0003-4819-133-9-200011070-00010. View

14.

Margaglione M, Colaizzo D, DAndrea G, Brancaccio V, Ciampa A, Grandone E . Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost. 2000; 84(5):775-8. View

15.

Ezekowitz , James , Radford , Rickles , Redmond . Initiating and Maintaining Patients on Warfarin Anticoagulation: The Importance of Monitoring. J Cardiovasc Pharmacol Ther. 2000; 4(1):3-8. DOI: 10.1177/107424849900400102. View

16.

Wadelius M, Chen L, Downes K, Ghori J, Hunt S, Eriksson N . Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 2005; 5(4):262-70. DOI: 10.1038/sj.tpj.6500313. View

17.

Sconce E, Khan T, Wynne H, Avery P, Monkhouse L, King B . The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005; 106(7):2329-33. DOI: 10.1182/blood-2005-03-1108. View

18.

Marsh S, King C, Porche-Sorbet R, Scott-Horton T, Eby C . Population variation in VKORC1 haplotype structure. J Thromb Haemost. 2006; 4(2):473-4. DOI: 10.1111/j.1538-7836.2006.01759.x. View

19.

King B, Khan T, Aithal G, Kamali F, Daly A . Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics. 2004; 14(12):813-22. DOI: 10.1097/00008571-200412000-00004. View

20.

White R, Beyth R, Zhou H, Romano P . Major bleeding after hospitalization for deep-venous thrombosis. Am J Med. 1999; 107(5):414-24. DOI: 10.1016/s0002-9343(99)00267-3. View